Many eyes watching closelyGAP could very well be on the verge of such partnership...given the media attention of late. I wounder what the SP would be upon such announcement. Nothing but blue sky.
PharmaGap is pursuing a strategy to partner its lead drug candidates at the pre-clinical or early clinical trial stage. The Company recognizes that its strengths rest in drug design and “proof of principle” validation and that larger pharmaceutical/biotech partners have the resources necessary to move the Company’s compounds into human clinical use.
PharmaGap is a spin-out from Canada’s premier biological research organization, the National Research Council of Canada. Offices and labs are located in Ottawa, Ontario, Canada.
The Company’s lead drug candidate, PhGα1, targets and inhibits the activity of PKC in cancer cells. This novel drug is representative of a new class of targeted therapeutics now in development by the pharmaceutical industry that are designed to specifically target molecular defects within a cancer cell, rather than killing cancer cells in general via traditional toxic chemotherapeutics.